Prior adherence to recommended lipid control targets in patients admitted for acute coronary syndrome.

Abstract

INTRODUCTION AND OBJECTIVES:

Optimal lipid control is difficult to attain. We assessed preadmission achievement of the European Society of Cardiology targets for low-density lipoprotein-cholesterol (LDL-C) control in patients admitted for acute coronary syndrome.

METHODS:

Fasting LDL-C levels were measured in 3164 patients admitted between 2010 and 2017. We assessed the frequency of adequate LDL-C control, with targets defined according to individual cardiovascular risk, and the predictors of inadequate control.

RESULTS:

The median LDL-C value was 104 (80-130) mg/dL. Most patients had high or very high cardiovascular risk and only 34.2% had LDL-C levels below the recommended target for their estimated risk. Achievement of LDL-C goals increased moderately throughout the study period. Adequate LDL-C control was inversely associated with patient risk. Dyslipidemia, active smoking, diabetes mellitus, and body mass index ≥ 25 were independent predictors of inadequate lipid control, while ongoing statin therapy was associated with adequate control.

CONCLUSIONS:

Only slightly more than one third of patients admitted for acute coronary syndrome meet recommended LDL-C targets on admission. There is broad scope for improvement in primary and secondary prevention, especially among patients who are overweight or have other cardiovascular risk factors.

• Authors: Laia Milà, José A Barrabés, Rosa-Maria Lidón, Antonia Sambola, Jordi Bañeras, Gerard Oristrell, Agnès Rafecas, David García-Dorado
• Journal: Revista espanola de cardiologia (English ed.) (Rev Esp Cardiol (Engl Ed)) Vol. 73 Issue 5 Pg. 376-382 (May 2020) ISSN: 1885-5857 [Electronic] Spain
• PMID: 31706709 (Publication Type: Journal Article)
• Copyright: Copyright © 2019 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Chemical References

• Anticholesteremic Agents
• Cholesterol, LDL
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Lipids

Topics

• Acute Coronary Syndrome (blood, diagnosis)
• Aged
• Anticholesteremic Agents (administration & dosage, therapeutic use)
• Cholesterol, LDL (blood)
• Dyslipidemias (drug therapy, epidemiology)
• Female
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Lipids (blood)
• Male
• Medication Adherence
• Middle Aged
• Risk Factors
• Treatment Outcome